1. Home
  2. ILMN vs ZTS Comparison

ILMN vs ZTS Comparison

Compare ILMN & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$211.37

Market Cap

32.3B

Sector

Health Care

ML Signal

HOLD

Logo Zoetis Inc.

ZTS

Zoetis Inc.

SELL

Current Price

$73.97

Market Cap

32.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ILMN
ZTS
Founded
1998
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.3B
32.5B
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
ILMN
ZTS
Price
$211.37
$73.97
Analyst Decision
Hold
Buy
Analyst Count
17
12
Target Price
$124.24
$154.18
AVG Volume (30 Days)
1.6M
3.7M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
1.86%
EPS Growth
170.87
10.05
EPS
2.22
3.08
Revenue
$4,343,000,000.00
$9,467,000,000.00
Revenue This Year
$6.47
$5.63
Revenue Next Year
$5.58
$4.77
P/E Ratio
$95.07
$23.90
Revenue Growth
N/A
2.28
52 Week Low
$88.00
$71.00
52 Week High
$231.81
$149.75

Technical Indicators

Market Signals
Indicator
ILMN
ZTS
Relative Strength Index (RSI) 54.52 44.06
Support Level $182.76 $73.02
Resistance Level $231.81 $78.74
Average True Range (ATR) 9.45 2.10
MACD -0.77 -0.10
Stochastic Oscillator 51.24 3.11

Price Performance

Historical Comparison
ILMN
ZTS

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

About ZTS Zoetis Inc.

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Share on Social Networks: